New targeted therapy for advanced lung cancer after EGFR treatment
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new targeted therapy (vebreltinib plus PLB1004) against standard chemotherapy for people with advanced non-small cell lung cancer that has a specific change (EGFR mutation) and MET protein, and has stopped responding to earlier EGFR treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have advanced or metastatic non-small cell lung cancer (stage IIIB or IV).
- Your cancer must have an EGFR mutation and MET protein (tested by a biopsy).
- You must have at least one tumor that can be measured.
- You must be able to perform daily activities (ECOG score 0 or 1).
- You must not have ALK or ROS1 mutations.
- You must not have untreated or unstable brain metastases that cause symptoms.
- You must have recovered from side effects of previous treatments (except hair loss).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (Vebreltinib and PLB1004) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has developed MET amplification or overexpression after previous EGFR-targeted therapy. The goal is to see if this combination can help shrink tumors or slow their growth.
This trial tests a combination of two targeted drugs (vebreltinib and PLB1004) as the first treatment for people with a specific type of advanced lung cancer that has both an EGFR mutation and high MET protein. It may offer a new option for those who haven't had treatment yet.
This trial tests a targeted drug (Vebreltinib) combined with standard chemotherapy in people with a specific type of advanced non-squamous lung cancer that has a MET gene change (amplification or overexpression). The goal is to see if this combination works better than chemo alone.
This study tests a new targeted pill (vebreltinib) for people with advanced non-small cell lung cancer that has a specific gene change (MET exon 14 mutation). It is for people who have not had much or any prior treatment. The goal is to see if this medicine can shrink tumors and improve outcomes.
This study tests a new pill called PLB1004 for people whose lung cancer has a specific EGFR mutation (exon 20 insertion). It is for those who have not yet had any treatment for their advanced cancer.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.